VENUS REMEDIES LIMITED
Snapshot
What the business is, and whether it's a good one at a fair price.
Operates in the pharmaceuticals and biotechnology space, reporting standalone revenue from operations of Rs 768.73 crore in FY26 against Rs 644.47 crore the year before and consolidated net profit of Rs 102.78 crore. The business carries out in-house Research and Development, with its R&D unit receiving renewal of the government's DSIR recognition in 2026. Operations extend overseas through a wholly-owned German subsidiary, Venus Pharma GmbH, which is currently undergoing restructuring with parent support pledged; the auditor has flagged Rs 28.60 crore of share application money outstanding at this subsidiary. The cost base is dominated by materials, which absorb 50.4% of revenue, while employees account for 11.5% and other operating expenses for 19.0%, leaving an EBITDA margin of 20.77% in FY26. The Board has recommended revisions to the Memorandum of Association to expand the company's stated scope into biotechnology, digital and telehealth businesses, subject to shareholder approval at the 37th AGM on August 20, 2026.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from VENUS REMEDIES LIMITED's filed financials and exchange disclosures
What does VENUS REMEDIES LIMITED do?
VENUS REMEDIES LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol VENUSREM.
Is VENUS REMEDIES LIMITED profitable?
Yes. Over the trailing twelve months VENUS REMEDIES LIMITED reported a net profit of ₹116 Cr on revenue of ₹811 Cr.
Does VENUS REMEDIES LIMITED pay a dividend?
Not in the latest reported year — VENUS REMEDIES LIMITED's dividend payout for FY26 was nil.
Is VENUS REMEDIES LIMITED debt-free?
Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹25 Cr of cash.
Is VENUS REMEDIES LIMITED expensive compared with its peers?
On trailing P/E, VENUS REMEDIES LIMITED ranks 35 of 158 in Pharmaceuticals — cheaper than 78% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the VENUS REMEDIES LIMITED share price move in a day?
On a typical session VENUS REMEDIES LIMITED moves 2.42% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track VENUS REMEDIES LIMITED's announcements?
Every NSE and BSE filing by VENUS REMEDIES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.